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Bilateral jaw fracture after long term treatment 
with bisphosphonates. A case report.
Abstract
Bisphosphonates represent type of medication used for treating numerous pathologies. In fact, more and more 
clinicians utilize bisphosphonates for dealing oncological diseases, rheumatic pathologies and severe osteoporosis. 
Despite its benefits, various undesirable side effects have also been associated with the use of these drugs. For 
instance, patients who receive bisphosphonates present a greater risk of suffering osteonecrosis of jaw. Indeed, 
the possibility of experiencing this complication is around 0,812% when bisphosphonates are administered 
intravenously. In contrast, the risk is about 0,01% with oral administration. However, when a tooth extraction is 
carried out the risk rises to 0,34%. This report presents the case of a 66 years old woman who suffered a bilateral 
jaw fracture after prolonged treatment with bisphosphonates. Interestingly, no invasive dental procedures were 
referred by patient. The main aim of this paper is to focus the attention on the serious complications that this 
treatment may show in the long term.
Resumen
Los bifosfonatos son fármacos ampliamente utilizados en el tratamiento de numerosas enfermedades. Diferentes 
profesionales utilizan los bifosfonatos para tratar complicaciones de patologías oncológicas, osteoporosis y pato-
logías reumatológicas. Sin embargo, a pesar de los efectos benéficos, existen efectos secundarios consecuente al 
utilizo de este tipo de medicamento. Por ejemplo, la osteonecrosis maxilar es más frecuente en pacientes trata-
dos con bifosfonatos. En este sentido, la posibilidad de desarrollar osteonecrosis maxilar es del 0,812% cuando la 
medicación es administrada por vía intravenosa y del 0,01% en caso de administración oral. Además, cuando se 
realiza una extracción dental el riesgo incrementa de un 0,34%. Este artículo presenta el caso de una paciente de 
66 años que sufrió una fractura bilateral y espontanea de la mandíbula tras el utilizo de bifosfonatos durante un 
largo periodo de tiempo. Es importante enfatizar que, en este caso, el paciente no había sido sometido a inter-
venciones de cirugía oral en los meses previos. El principal objetivo de este estudio es focalizar la atención sobre 
las posibles complicaciones provocadas por este medicamento.
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INTRODUCTION:
Several studies demonstrated that Bisphosphonates are an 
important and well-established drug in the treatment of several 
diseases (1). Its represent the first-line treatment for malignant hy-
percalcemia and bone metastasis (2). Moreover, bisphosphonates 
are also used for treatment of paget’s disease, osteoporosis, and 
multiple myeloma (3). When administered, bisphosphonates are 
deposited into the bones, due to high affinity for hydroxyapatite, 
and are accumulated through time (4). It is common knowledge 
that patients who receive these medicines have an increased risk 
of suffering ONJ (5) (6). This risk is around 0,812% if bisphosphona-
tes are administered intravenously. Whereas, is less for oral admi-
nistration (0,01%). Notwithstanding, the risk rises to 0,34% when 
invasive dental procedures are performed in patients treated with 
this drugs (4).In this sense, professionals who prescribe bisphos-
phonates must strongly advise about this complication and dental 
extractions should be avoided in these case (7) (8) (9). 
CASE REPORTS:
We describe the case of a 66-year-old woman who came to 
the emergency service of our Hospital with mouth pain, active oral 
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intravenous antibiotic treatment was administered and a maxillo-
facial surgeon was contacted. A careful anamnesis revealed that 
patient received long term therapy with bisphosphonates. In fact, 
she was diagnosed with breast cancer eight years ago. Intraoral 
examination showed bone exposure with active suppuration of 
purulent matter in the third and fourth quadrants of the jaw. The 
rest of the physical examination was normal. Bearing in mind the 
patient’s history, we decided to perform an orthopantomography. 
This test showed a major area of bone degeneration and a bilate-
ral non-displaced fracture of the mandible. Considering all this, the 
patient was hospitalized in order to maintain intravenous antibio-
tic treatment. Treatment response was positive since the earliest 
days. In view of that, we continue with this conservative approach 
during ten days. We also perform a rigid blockage of the jaw and 
a complete debridement of necrotic tissue. The clinic substantially 
improve during the hospital stay. Finally, she was discharged from 
hospital after two weeks with oral antibiotic for other four wee-
ks. Importantly, jaw blockage was also maintained during 4 weeks. 
Patient was reviewed every 3-4 weeks for one year. It is important 
to underline that during the follow-up, we observed that patient 
remained asymptomatic.
DISCUSSION:
In recent times, the use of bisphosphonates is growing rapidly. 
In fact, oral and intravenous preparations of this drugs are daily 
prescribed for treating pathologies such as osteoporosis, rheumatic 
pathologies and several metabolic bone diseases. In this light, the 
main aim of the present report is to show the serious consequen-
ces that bisphosphonates could provoke on the jaw bone. In our 
opinion, these complications are often underestimated by a vast 
number of clinicians. This report raises three central points. First, 
conservative treatment is preferable where possible in cases of 
ONJ. In this line, unnecessary manipulation of the oral cavity should 
be avoided in these patient. Second, an accurate oral examination 
is mandatory before the beginning of bisphosphonate treatment. 
In fact, the existence of dental pathology need to be diagnosed and 
treated prior to commencement with antiresorptive medication. 
This attitude might reduce the frequency of ONJ (10). Third, is the 
consideration that bisphosphonates should be used with caution. 
In fact, patients who receive bisphosphonates need a close moni-
toring for life. In addition, there are no effective treatments for this 
disease.
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Fig 1. Bilateral jaw fracture.
Fig 2. Jaw fracture evolution during patient follow-up 
(one months after diagnosis)
Fig 3. Jaw fracture evolution during patient follow-up (nine months 
after fracture reduction)
